PPT-Audit of EGFR mutation testing in patients with proven Non-

On behalf of the North of England Cancer Network Lung NSSG Dr Naomi Chamberlin Dr Ann Ward Aims Overview of brief Method Contributing Trusts Results Discussion Overview of brief To gather data on all patients with a diagnosis of nonsmall cell lung cancer across the Network for whom specimens have been sent for EGFR mutation testing. Colin Reisterer and Nick Swenson. S. . Maheswaran. et al. . The New England Journal of Medicine. . 2007. http://www.all-cancer-treatments.com/types-of-lung-cancer.html. Clinical background: Non-small cell lung cancer (NSCLC). TKI. s. . and . related. . treatment . strategies. Rafal . Dziadziuszko. Medical. . University. of Gdańsk, Poland. 16th European . Congress. „. Perspectives. in . Lung. Cancer. ” . Torino. from the. Technology of the . Future. into. . the. Technology of the . Present. Paul . Ammann. 2015 Mutation Workshop Keynote. Graz, Austria . April 13, 2015. 1. A Poll. How many of you. Agree?. Disagree?. David Pryor. Mutation-Based Testing. Same basic goal as Code Coverage. Evaluate the tests. Determine “how much” code exercised. Mutation testing goes beyond checking which lines of code were executed. Beth . Eaby. -Sandy, MSN, CRNP, OCN. ®. Nurse Practitioner. Abramson Cancer Center. University of Pennsylvania Health System. Disclosures of Conflicts of Interest. Ms. Eaby-Sandy, MSN, CRNP, OCN. ®. from the. Technology of the . Future. into. . the. Technology of the . Present. Paul . Ammann. 2015 Mutation Workshop Keynote. Graz, Austria . April 13, 2015. 1. A Poll. How many of you. Agree?. Disagree?. The Coming Paradigm Shift. Faculty. Suresh S. Ramalingam, MD. Professor of Hematology/Oncology . Director, Lung . Cancer Program . Winship Cancer Institute. Emory University. Atlanta, . Georgia. Program Goals. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. At initial diagnosis . 0. At first relapse . 0. At second relapse . Medical Oncologists. Gynecologic Oncologists. 12. 0. 0. 12. 2. In general, what type of mutation testing do you order for patients with ovarian cancer at initial diagnosis?. Cécile Jovelet. Postdocoral. . fellow. Translational. . research. . lab. Gustave Roussy Institute, France. Introduction . 12/04/2017. 2. Lung cancer: . third most frequent cancer. Non-Small Cell Lung Cancer (NSCLC): 80% cases of lung cancer. I.Antonucci. , . Molecular Genetics. “G. . d'Annunzio. ” University, . Chieti. Request. of . genetic. . testing. Genetic counseling: a multistep process. WHO IS A CANDIDATE FOR CANCER GENETIC COUNSELING AND TESTING?. John A. Clark, . Haitao. Dan, Robert M Hierons. An example: cruise control. Question. What happens in . no_vehicle_in_front. if brake and level=increase?. Another question. What happens in . no_vehicle_in_front. Ana Rima. Lung Cancer: Incidence and Mortality. New cases in 2013: 228,190. 40% with stage IV disease at presentation (~ 90,000). ~ 160,000 deaths in 2012, comparable to prostate, pancreas, breast, and colon cancer combined. Gregory J. Riely. November 2021. What about those other EGFR mutations?. EGFR. ALK. ROS1. BRAF. RET. MET Exon14. KRAS G12C. EGFR exon 20. ERBB2/HER2. NTRK. Key Subtypes. EGFR exon 20 insertions . ~1% of people with NSCLC.